Attempting to Avoid Chemotherapy in CLL with Lenalidomide and Rituximab - a podcast by American Society of Clinical Oncology (ASCO)

from 2014-05-27T14:07:42

:: ::

The current study, reporting on the upfront use of lenalidomide and rituximab in CLL, suggests high response rates and excellent tolerability in younger as well as older patients, albeit with a modest median progression-free survival.